The study, for presentation at the American College of Gastroenterology annual meeting in Washington, D.C., examined drug interventions for IBS deemed to be of merit by a task force of the group . The study compared the therapies based on “number needed to harm statistics” from large clinical trials.
In evaluating a drug’s effectiveness, two common measures are the number needed to treat (the average number of patients who must take a therapy before one is treated successfully) and the number needed to harm (how many patients must be treated before the adverse effects of a therapy are bad enough that one patient drops the medication).
“For patients who suffer from irritable bowel syndrome, historically effective treatment options have been very scarce,” said Mark Pimentel, MD, director of the G.I. Motility Program at Cedars-Sinai Medical Center and a lead author on the study. “Unfortunately, many of the treatments approved for IBS cause intolerable complications for many patients. This underscores the need for us to continue to seek new therapies for this disease, which dramatically harms quality of life for millions of people.”
The study looked at the most common and highly rated treatments for the condition. Three of these treatments are for diarrhea-predominant IBS: tricyclic antidepressants; alosetron – a drug that slows movement of stool in the gut; and rifaximin, an antibiotic absorbed only in the gut. The difference among these drugs was striking. For tricyclic inhibitors, the number needed to harm was 18.3, while the number needed to harm for alosetron was 19.4. For rifaximin, the number needed to harm was 8,971.
The study also found that for every 2.3 and 2.6 patients who benefitted from tricyclic inhibitors and alosetron respectively, one patient was harmed by the study medication and had to withdraw. For rifaximin, this number was 897.
“This further validates previous research we’ve done on rifaximin as a safe and effective treatment for IBS,” Pimentel said. “Now, not only have our previous clinical studies shown that this selectively absorbed antibiotic is the first treatment for IBS patients in which patients continue to have relief from their symptoms after stopping the drug – compared to other available treatments for the condition, it statistically has caused fewer adverse side effects.”
In an article published earlier this year in the New England Journal of Medicine, the ground-breaking therapy developed at Cedars-Sinai found through two double-blind trials that patients who suffered from diarrhea prominent IBS reported relief from bloating, less abdominal pain and improved stool consistency for up to 10 weeks. While the concept of bacteria playing a key role in IBS was controversial when first unveiled a decade ago, this research confirms that bacteria in the gut trigger the symptoms of the chronic condition, affecting an estimated 30 million people in the United States.
Rifaximin is marketed by Salix Pharmaceuticals Inc. Pimentel discovered the use of rifaximin for IBS, and Cedars-Sinai holds patent rights to this discovery and has licensed rights to the invention to Salix. Dr. Pimentel is a consultant to Salix Inc, and serves on its scientific advisory board.
Nicole White | Cedars-Sinai News
Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung
Scientists reveal source of human heartbeat in 3-D
07.08.2017 | University of Manchester
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
23.08.2017 | Life Sciences
23.08.2017 | Life Sciences
23.08.2017 | Physics and Astronomy